Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we analysed esketamine-related adverse events (AEs) to detect and characterize relevant safety signals. Methods: We used the consolidated case/non-case approach to estimate the reporting odds ratio (ROR) and information component (IC) with relevant confidence intervals (95% CI) for esketamine-related AEs with ≥4 counts. Comparisons between serious and non-serious AEs were performed using non-parametric tests. Results: The FAERS database contained 962 cases of esketamine-related AEs, with signals detected for several AEs, such as dissociation (ROR = 1,612.64, 95% CI = 1,354.63, 1,919.79; IC = 8.19, 95% CI = 7.96, 8.35), sedation (ROR = 238.46, 95% CI = 202.98, 280.15; IC = 7, 95% CI = 6.75, 7.18), feeling drunk (ROR = 96.17, 95% CI = 61.42, 150.57; IC = 4.84, 95% CI = 4.09, 5.36), suicidal ideation (ROR = 24.03, 95% CI = 18.72, 30.84; IC = 4.31, 95% CI = 3.9, 4.61), and completed suicide (ROR = 5.75, 95% CI = 3.18, 10.41; IC = 2.25, 95% CI = 1.23, 2.94). Signals for suicidal and self-injurious ideation, but not suicide attempt and completed suicide, remained when comparing esketamine to venlafaxine. Females and patients receiving antidepressant polypharmacy, co-medication with mood stabilizers, antipsychotics, benzodiazepines, or somatic medications were more likely to suffer from serious versus non-serious AEs (χ 2 = 125.29, p < 0.001, χ 2 = 9.08, p = 0.003, χ 2 = 8.14, p = 0.004, χ 2 = 19.48, p < 0.001, χ 2 = 25.62, p < 0.001, and χ 2 = 16.79, p < 0.001, respectively). Conclusions: Esketamine may carry a clear potential for serious AEs, which deserves urgent clarification by means of further prospective studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, a pharmacovigilance analysis found some specific patients reported more serious adverse events (women, obese people, people with comorbidities and with poly-pharmacy) [25].”
In the citing paper
“Possible safety issues have indeed been described in post-marketing studies [25, 52].”
In the citing paper
“As detailed above, esketamine-associated adverse events across trials have raised significant concern, particularly with regard to inducing suicidality [115].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [115]
Citations
Cites
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
Ford, I., & Norrie, J. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510059 · Cited by 1,405
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
Explanatory and Pragmatic Attitudes in Therapeutical Trials
Schwartz, D., & Lellouch, J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.012 · Cited by 1,252
Explanatory and pragmatic attitudes in therapeutical trials
Schwartz, D., & Lellouch, J. (1967) · Journal of Chronic Diseases · doi:10.1016/0021-9681(67)90041-0 · Cited by 1,185
The reporting odds ratio and its advantages over the proportional reporting ratio
Rothman, K. J., Lanes, S., & Sacks, S. T. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1001 · Cited by 1,111
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Quantitative signal detection using spontaneous ADR reporting
Bate, A., & Evans, S. J. W. (2009) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1742 · Cited by 912
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Cited by
Items 101–142 of 142
Esketamine for treatment-resistant depression in adults
Gastaldon, C., Laurenzi, P. F., Schoretsanitis, G., Papola, D., Cristea, I. A., Naudet, F., Ostuzzi, G., & Barbui, C. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015071 · Cited by 2
Self-citationIntranasal esketamine for depression: Not so special K
Rosenman, S. J. (2022) · Australasian Psychiatry · doi:10.1177/10398562221093870 · Cited by 2
“A common unwanted effect is ‘dissociation’, the psychological disconnection from the body and the world for an hour or two that is often misleadingly called ‘psychotic’.(5) The dissociative effect seems to be related to higher doses and faster absorption and is less likely with lower doses and slow injection.”
BackgroundChallenges for esketamine nasal spray in China: use and management
Wu, J., Gu, J., Qiu, L., Jin, X., & Zhou, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1429435 · Cited by 2
Cho, J., Jo, H., Pizzol, D., Smith, L., & Park, J. (2024) · Life Cycle · doi:10.54724/lc.2024.e11 · Cited by 2
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 2
Intranasal esketamine and manic symptoms: A disproportionality analysis in EudraVigilance
Akhrimenko, V., García, M., Aguirre, C., Aguirre, U., Morera‐Herreras, T., Palacios, R. H., Medrano, J. F. F., & Lertxundi, U. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.05.008 · Cited by 2
Fang, Q., Huang, F., Liang, J., Chen, Y., Li, C., Zhang, M., Wu, X., & Luo, W. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2182288 · Cited by 2
Reply to the Comments by Doherty et al.
Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000511830 · Cited by 2
Self-citationNaudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Pabic, E. L., & Cristea, I. A. (2025) · medRxiv · doi:10.1101/2025.07.17.25331696 · Cited by 2
Self-citationPlöderl, M., Cooper, R. E., Walker, T., Shah, V., Horowitz, M. A., Volkmann, C., & Moncrieff, J. (2025) · medRxiv · doi:10.1101/2025.08.19.25333796 · Cited by 2
“On the other hand, post marketing data suggests that esketamine may be associated with an increase in suicidal ideation and suicides [12] and chronic, recreational ketamine misuse is associated with depression [13–15].”
Progress of Clinical Application of Esketamine in Abdominal Tumor Surgery in Elderly Patients
Xie, J.-X., & Zhou, L.-W. (2025) · Current anesthesiology reports · doi:10.1007/s40140-025-00694-9 · Cited by 1
Wang, L., Xiong, R., Liu, H., Zhang, S., Xu, L., & Lai, X. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05108-z · Cited by 1
“There are several studies on esketamine-related ADEs based on FAERS (Gastaldon et al. 2020; Yang and Chen 2024), none of which focus on age.”
Sun, X., Guo, D., & Wang, L. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004745 · Cited by 1
Bonnet, U., Scherbaum, N., Juckel, G., & Bschor, T. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2846-4275 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
Wang, L., Yu, S., Zhang, X., Jiang, Z., Jin, H., & Gong, G. (2025) · American Journal of Translational Research · doi:10.62347/edns9849 · Cited by 1
Qian, J., Truong, B., & Tanni, K. A. (2021) · BioDrugs · doi:10.1007/s40259-021-00474-x · Cited by 1
“In addition, the use and comparison of the group of these serious AEs as the key outcome for post-marketing safety signal detection for pharmaceutical products has been widely published in the pharmacovigilance literature [5, 6].”
BackgroundXing, X., Wang, K., & Dong, X. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01728-4 · Cited by 1
“We adopted the same deduplication procedure as many other studies, such as those by Nie et al. [3], Gastaldon et al. [4] and Omar et al. [5], following the related file by FARES database.”
Are we repeating mistakes of the past? A review of the evidence for esketamine – CORRIGENDUM
Horowitz, M. A., & Moncrieff, J. (2021) · The British Journal of Psychiatry · doi:10.1192/bjp.2021.40
Moncrieff, J., & Horowitz, M. A. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.59
Shaji, A., Sony, A., Mytheen, S., & Tom, A. A. (2023) · Research Square · doi:10.21203/rs.3.rs-2527867/v1
Müller‐Dahlhaus, F., Junginger, M., & Kelsch, W. (2024) · PSYCH up2date · doi:10.1055/a-2276-4802
Chapter 21. Ketamine and Esketamine
Mathai, D. S., & Mathew, S. J. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as21
A Review of the Progress in Clinical Application of Esketamine
黄, 芳. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.14123165
Application Progress of Esketamine in Non-Endotracheal Intubation General Anesthesia Surgery
王, 欣. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.153621
Jang, Y. M., Kim, M. W., Ji, J. H., Hwang, S., Choe, Y., Shin, J., & Choi, H. (2025) · Journal of Pharmacoepidemiology and Risk Management · doi:10.56142/perm.25.0008
Cho, J., Lee, K., Woo, S., Park, J., Jo, H., Oh, J., Kim, T. H., Wen, X., Fond, G. B., Boyer, L., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120629
Shi, M. Y., Wang, T., Wang, W., Wang, J., Li, L., Bo, L., & Wang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1728802
Garel, N. (2024) · eScholarship@McGill (McGill) · doi:10.82308/13771
Kremer, M. (2024) · MOnAMi (Hochschule Mittweida Hochschulbibliothek)
Abordagem atual na seleção de medicamentos emergentes na Depressão Resistente
Martins, M. S. T. V. D. B. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Lejman, A., Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Mazurkiewicz, A., Sidor, H., & Wołosik, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4697
Wang, L., Xiong, R., Liu, H., Zhang, S., Tong, Y., Hu, G., & Lai, X. (2026) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/2842468
Impact et faisabilité du partage des données individuelles issues de la recherche clinique
Pellen, C. (2024) · theses.fr (ABES) · doi:10.70675/ef81f3a2z0c0cz4757za338z831065d04fdc
Qu, Y., Li, S., Tian, L., Tian, X., & Wu, Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1792570 · Cited by 1
“…et al., 2022; Ouyang and Li, 2025), but treatment is accompanied by dizziness, nausea, dissociation, and increased risk of elevated blood pressure (Gastaldon et al., 2021; Ionescu et al., 2021; Zorn et al., 2021; Yang et al., 2022), and dose-specific evidence remains limited (Hock et al., 2022).”
Chen, J. F., Hsu, C., Fang, Y.-Y., Tseng, P., Yu-Chen, K., Hsu, T.-W., & Liang, C.-S. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111764
Xing, X., Wang, K., Feng, Y., Wu, C., Jia, L., Li, H., Wen, Z., Tang, Y., Wang, Z., Zhang, X., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1822543
“The reporting odds ratio (ROR) was considered statistically signi fi cant if the lower limit of the ninety-fi ve percent con fi dence intervals (CIs) was greater than 1, while the Bayesian information component (IC) was deemed signi fi cant if the lower limit of the CI was above 0 (25).”
Huang, X., Zhou, R., Xu, C., Qian, H., Huang, Y., Gao, Z., 赵秋龙, Xu, M., Shi, S., 于爱玲, et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004159
Wang, Y., Storaci, A. S., Alexander, G. C., & Gibbons, J. B. (2026) · Drug Safety · doi:10.1007/s40264-026-01722-1
Omachonu, R. A., Uzuh, S. A., Akinola, K., Ovabor, K., & Odibo, A. (2026) · Cureus · doi:10.7759/cureus.117858
Suicidality during intranasal (es)ketamine treatment: A retrospective cohort study
Ehrt‐Schäfer, Y., Schoretsanitis, G., Seifritz, E., Olbrich, S., & Ferrea, S. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122647
Self-citationLee, K., Jung, J. H., Lee, J., Lee, J. W., Jeong, C.-H., Kim, E., & Lee, S. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01849-5
Metadata
- Authors
- Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C., & Schoretsanitis, G.
- Affiliations
- University of Verona (IT)
- University of Bologna (IT)
- Northwell Health (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020-08-27
- Volume
- 90
- Issue
- 1
- Pages
- 41-48
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3082360571
- Cited by
- 134
- References
- 54
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 25 · 2023: 22 · 2022: 25 · 2021: 16 · 2020: 2
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, treatment-resistant depression, post-marketing safety, adverse event signals, dissociation, sedation, suicidal ideation, suicide mortality, venlafaxine, mood stabilizers, FDA Adverse Event Reporting System, reporting odds ratio, information component, serious adverse events, sex differences in adverse events
- MeSH terms
- Female, Humans, Ketamine, Prospective Studies, Adverse Drug Reaction Reporting Systems, Marketing, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.